Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma

Molecular Carcinogenesis

Volumn 49, Issue 11, 2010, Pages 944-950

  Cao, Yun ^a   Miao, Xiao Ping ^b   Huang, Ma Yan ^a   Deng, Ling ^a   Lin, Dong Xin ^b   Zeng, Yi Xin ^a   Shao, Jian Yong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b CANCER HOSPITAL   (China)

Author keywords

Cancer; Head and neck; Molecular epidemiology; Single nucleotide polymorphism

Indexed keywords

FAS ANTIGEN; FAS LIGAND; FAS PROTEIN, HUMAN; FASLG PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GENDER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SMOKING HABIT; CASE CONTROL STUDY; CHINA; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; NASOPHARYNX TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

NICOTIANA TABACUM;

ANTIGENS, CD95; CASE-CONTROL STUDIES; CHINA; FAS LIGAND PROTEIN; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SMOKING;

EID: 78149342132     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20676     Document Type: Article

References (35)

1. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 421-429.
2. Geser A, Charnay N, Day NE, de-The G, Ho HC. Environmental factors in the etiology of nasopharyngeal carcinoma: Report on a case-control study in Hong Kong. IARC Sci Publ 1978: 20: 213-229.
3. Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, Yu MC. Non-dietary risk factors for nasopharyngeal carcinoma in Shanghai, China. Int J Cancer 2000; 85: 364-369.
4. Niller HH, Wolf H, Minarovits J. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin Cancer Biol 2009; 19: 158-164.
5. Shao JY, Wang HY, Huang XM, et al. Genome-wide allelotype analysis of sporadic primary nasopharyngeal carcinoma from southern China. Int J Oncol 2000; 17: 1267-1275.
6. Hildesheim A, Apple RJ, Chen CJ, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 2002; 94: 1780-1789.
7. Cao Y, Miao XP, Huang MY, et al. Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population. BMC Cancer 2006; 6: 167.
8. Tiwawech D, Srivatanakul P, Karalak A, Ishida T. Cytochrome P450 2A6 polymorphism in nasopharyngeal carcinoma. Cancer Lett 2006; 241: 135-141.
9. Guo X, O'Brien SJ, Zeng Y, Nelson GW, Winkler CA. GSTM1 and GSTT1 gene deletions and the risk for nasopharyngeal carcinoma in Han Chinese. Cancer Epidemiol Biomarkers Prev 2008; 17: 1760-1763.
10. Bei JX, Li Y, Jia WH, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 2010; 42: 599-603.
11. Nam JM, McLaughlin JK, Blot WJ. Cigarette smoking, alcohol, and nasopharyngeal carcinoma: A case-control study among U.S. whites. J Natl Cancer Inst 1992; 84: 619-622.
12. Vaughan TL, Shapiro JA, Burt RD, et al. Nasopharyngeal cancer in a low-risk population: Defining risk factors by histological type. Cancer Epidemiol Biomarkers Prev 1996; 5: 587-593.
13. Cheng YJ, Hildesheim A, Hsu MM, et al. Cigarette smoking, alcohol consumption and risk of nasopharyngeal carcinoma in Taiwan. Cancer Causes Control 1999; 10: 201-207.
14. Shanmugaratnam K, Tye CY, Goh EH, Chia KB. Etiological factors in nasopharyngeal carcinoma: A hospital-based, retrospective, case-control, questionnaire study. IARC Sci Publ 1978: 20: 199-212.
15. Armstrong RW, Imrey PB, Lye MS, Armstrong MJ, Yu MC, Sani S. Nasopharyngeal carcinoma in Malaysian Chinese: Occupational exposures to particles, formaldehyde and heat. Int J Epidemiol 2000; 29: 991-998.
16. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004; 96: 1030-1036.
17. Zhang X, Miao X, Sun T, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005; 42: 479-484.
18. Yang M, Sun T, Wang L, et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 2008; 14: 3230-3236.
19. Tsai ST, Fang SY, Jin YT, Su IJ, Yang BC. Analysis of the expression of Fas-L in nasopharyngeal carcinoma tissues. Oral Oncol 1999; 35: 421-424.
20. Ho SY, Guo HR, Chen HH, Hsiao JR, Jin YT, Tsai ST. Prognostic implications of Fas-ligand expression in nasopharyngeal carcinoma. Head Neck 2004; 26: 977-983.
21. Min H, Hong M, Ma J, et al. A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys 1994; 30: 1037-1042.
22. Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 2002; 12: 309-315.
23. Wu W, Wang HD, Guo W, et al. Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells. J Exp Clin Cancer Res 2010; 29: 49.
24. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
25. Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000; 78: 312-325.
26. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997; 34: 577-582.
27. Sibley K, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003; 63: 4327-4330.
28. Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: A candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003; 170: 132-138.
29. Brennan P. Gene-environment interaction and aetiology of cancer: What does it mean and how can we measure it? Carcinogenesis 2002; 23: 381-387.
30. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-795.
31. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 1998; 58: 2057-2062.
32. Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 2003; 201: 268-277.
33. Suzuki N, Wakisaka S, Takeba Y, Mihara S, Sakane T. Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell Immunol 1999; 192: 48-53.
34. Ng CC, Yew PY, Puah SM, et al. A genome-wide association study identifies ITGA9 conferring risk of nasopharyngeal carcinoma. J Hum Genet 2009; 54: 392-397.
35. Tse KP, Su WH, Chang KP, et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am J Hum Genet 2009; 85: 194-203.